Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 20/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.54 |
| ▸ | RAF1 | P04049 | 5/20 | 0.53 |
| ▸ | YES1 | P07947 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16195447 | 0.89 | BRPF1 (0.56) | BRAFCYP2C9RAF1YES1 | |
| SCHEMBL13837940 | 0.88 | EPHB4 (0.51) | BRAF | |
| SCHEMBL14819854 | 0.79 | BRAF (0.69) | BRAFCYP2C9RAF1YES1 | |
| SCHEMBL13735473 | 0.78 | BRAF (0.54) | BRAFCYP2C9RAF1YES1 | |
| SCHEMBL2196658 | 0.77 | BRAF (0.66) | BRAFCYP2C9RAF1YES1 | |
| SCHEMBL13734662 | 0.77 | BRAF (0.53) | BRAFCYP2C9RAF1YES1 | |
| SCHEMBL1698068 | 0.76 | BRAF (0.65) | BRAFCYP2C9RAF1YES1 | |
| SCHEMBL1697887 | 0.76 | BRAF (0.68) | BRAFCYP2C9RAF1YES1 | |
| SCHEMBL13736827 | 0.76 | BRAF (0.65) | BRAFCYP2C9RAF1YES1 | |
| SCHEMBL1697994 | 0.76 | BRAF (0.74) | BRAFCYP2C9RAF1YES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140323519-A1 | HETEROCYCLIC COMPOUNDS AS B-RAF INHIBITORS FOR TREATMENT OF CANCER | MERCK SHARP & DOHME CORP. (US) | 2014-10-30 | — | — | US | claimed |
| US-20140323519-A1 | HETEROCYCLIC COMPOUNDS AS B-RAF INHIBITORS FOR TREATMENT OF CANCER | MERCK SHARP & DOHME CORP. (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140323519-A1 | HETEROCYCLIC COMPOUNDS AS B-RAF INHIBITORS FOR TREATMENT OF CANCER | MERCK SHARP & DOHME CORP. (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140323519-A1 | HETEROCYCLIC COMPOUNDS AS B-RAF INHIBITORS FOR TREATMENT OF CANCER | MERCK SHARP & DOHME CORP. (US) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323519-A1 | HETEROCYCLIC COMPOUNDS AS B-RAF INHIBITORS FOR TREATMENT OF CANCER | BRAF, RAF1, NRAS | BRAF 1/4885CYP2C9 2859/4885RAF1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.